Neuropsychopharmacology editor resigns after failure to disclose conflict of interest

Charles Nemeroff has decided to resign as editor of the journal Neuropsychopharmacology after he co-authored a favorable article on a chest implant that treats depression and did not disclose his financial ties to Cyberonics, which manufactures the device, the Wall Street Journal reports.

The article, published last month in Neuropsychopharmacology, said that the device - which delivers mild electrical pulses to the vagus nerve in the neck - is "a promising and well-tolerated intervention that is effective in a subset of patients with treatment-resistant depression."

Nemeroff, chair of the Department of Psychiatry and Behavioral Sciences at Emory University, and seven of the eight other authors of the article serve as consultants for Cyberonics, and one of the authors was an employee of the company.

In an e-mail, the owner of Neuropsychopharmacology said that Nemeroff decided to resign, "in part, based on the recent adverse publicity to the journal."

Neuropsychopharmacology has published a correction that disclosed the financial ties of the authors of the article to Cyberonics (Armstrong, Wall Street Journal, 8/26).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Machine learning reveals sleep quality and anxiety as major predictors of depression